Previous studies have identified TERT promoter and TP53 mutations as early events in glioblastomas and other cancers.39–41 Our analysis reveals that high metabolic activity in glioblastoma lesions often correlates with key driver mutations in genes like TERT, NF1, TP53, FLG, SYNE1, and HMCN1. This evidence concerns the gene FLG and cancer.